- Home
- NVGS vs VOR Comparison
NVGS vs VOR Comparison
Compare NVGS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVGS | VOR |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | 76 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NVGS | VOR |
|---|---|---|
| Price | $22.15 | $23.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $21.50 | ★ $45.33 |
| AVG Volume (30 Days) | 397.7K | ★ 777.2K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.08 | $1.90 |
| 52 Week High | $24.36 | $49.95 |
Technical Indicators
Market Signals| Indicator | NVGS | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 63.23 |
| Support Level | $17.38 | $21.75 |
| Resistance Level | $22.86 | $24.34 |
| Average True Range (ATR) | 0.62 | 1.16 |
| MACD | 0.14 | -0.11 |
| Stochastic Oscillator | 87.85 | 68.32 |
Price Performance
Historical ComparisonAbout NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.